Skip to main content
Fig. 1 | BMC Cardiovascular Disorders

Fig. 1

From: Upregulation of CIRP by its agonist prevents the development of heart failure in myocardial infarction rats

Fig. 1

The effects of zr17-2 pretreatment on cardiac function and structure in MI rats. A The schematic image depicting the timeline of MI induction and treatment with CIRP agonist zr17-2. B Western blot analysis of the CIRP level in the hearts of the rats pretreated with zr17-2 before the induction of MI, GAPDH was used as an internal control. C Representative M-mode echocardiograms at the end of the experiment. D LVEF; E FS; F LVEDV; G LVESV; H LVIDd; I LVIDs; J IVSd; K LVPWd; MI, myocardial infarction; LVEF, left ventricular ejection fraction; FS: left ventricle fractional shortening; LVEDV: left ventricle end-diastolic volume; LVESV: left ventricle end-systolic volume; LVIDd: left ventricle internal diameter at end-diastole; LVIDs: left ventricle internal diameter at end-systole; IVSd: interventricular septum diameter at end-diastole; Data are expressed as the means ± SD; n = 4–6 in each group. *p < 0.5, ** p < 0.01, ***p < 0.001 and ****p < 0.0001

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us